Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down ... Cardiometabolic Health at Eli Lilly and Company, told Health.
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback